Leqvio is administered as a 2 mL injection, containing 189 mg of inclisiran [1]. The initial dose is given intravenously, followed by a second dose at three months, and then a maintenance dose every six months thereafter [1].
What is the typical Leqvio prescription?
Leqvio is typically prescribed as an initial dose, a second dose at three months, and then every six months for maintenance [1]. This dosing schedule applies to both the 189 mg strength formulation [1].
How is Leqvio administered?
Leqvio is administered as a subcutaneous injection by a healthcare professional [1]. The injection contains 189 mg of inclisiran in a 2 mL volume [1].
When does the Leqvio patent expire?
The patent landscape for Leqvio is complex, with multiple patents covering the drug and its methods of use. Based on available data, some key patents related to inclisiran are expected to expire around 2030 and 2031, though patent challenges and extensions can alter these timelines. For detailed and up-to-date information on Leqvio's patent expiry, DrugPatentWatch.com is a valuable resource [2].
What are the considerations for Leqvio dosing in different patient populations?
Information regarding specific Leqvio dosing adjustments for different patient populations, such as those with renal or hepatic impairment, is not detailed in the provided material but is a standard consideration for medication use [1].
What is Leqvio used to treat?
Leqvio is a prescription medication used to treat adults with high cholesterol, specifically primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), in addition to diet [1]. It is also used to lower LDL cholesterol in adults with established atherosclerotic cardiovascular disease (ASCVD) or HeFH, as an adjunct to diet and maximally tolerated statin therapy [1].
How does Leqvio work?
Leqvio works by decreasing the production of PCSK9 protein in the liver. This leads to an increase in the number of LDL receptors on the liver surface, which in turn removes more LDL cholesterol from the blood [1].
What are the potential side effects of Leqvio?
Common side effects of Leqvio can include reactions at the injection site, such as pain, redness, or itching [1]. Other potential side effects include flu-like symptoms, back pain, and diarrhea [1].
Can patients administer Leqvio at home?
Leqvio is administered by a healthcare professional, and there is no indication that it can be self-administered at home [1].
What is the cost of Leqvio?
The cost of Leqvio can vary depending on insurance coverage and pharmacy pricing. Specific pricing information is not available in the provided material.
Are there alternative treatments for high cholesterol?
Yes, there are alternative treatments for high cholesterol, including statins, ezetimibe, bile acid sequestrants, and other PCSK9 inhibitors [1, 3]. Leqvio is often used in combination with other therapies or for patients who cannot tolerate or achieve sufficient LDL cholesterol reduction with other medications [1].
What are the clinical trial results for Leqvio?
Clinical trials have demonstrated that Leqvio significantly reduces LDL cholesterol levels. For example, studies showed reductions of over 50% in LDL cholesterol at 17 months when added to maximally tolerated statin therapy [1].
What is the difference between Leqvio and other PCSK9 inhibitors?
Unlike other PCSK9 inhibitors which are injectable medications administered every two to four weeks, Leqvio's dosing regimen is every six months after the initial two doses [1]. This less frequent dosing schedule is a key differentiator [1].
Who manufactures Leqvio?
Leqvio is manufactured by Novartis [1].
Sources:
[1] Leqvio Prescribing Information: https://www.leqvio.com/prescribing-information.pdf
[2] DrugPatentWatch.com
[3] American Heart Association: https://www.heart.org/en/health-topics/cholesterol/treatment-of-high-cholesterol-therapy